Related Experiment Video
Updated: Aug 14, 2026
08:44
Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
Published on: November 11, 2014
[Gaucher's disease with D409H/D409H genotype. evolution with enzyme replacement therapy]
F Castelló Girona1, C Domínguez Luengo, M del Toro Riera
1Servicio de Pediatría. Hospital Materno-Infantil Vall d'Hebron. Barcelona. secrepa@cs.vhebron.es
Anales Espanoles De Pediatria
|March 23, 2001
Summary
Gaucher's disease, caused by glucocerebrosidase gene mutations, presents unique symptoms with the D409H variant. This case study tracks a young patient
Area of Science:
- Genetics and rare diseases
- Lysosomal storage disorders
- Pediatric neurology and cardiology
Background:
- Gaucher's disease results from mutations in the glucocerebrosidase gene.
- The D409H mutation is prevalent in Spain and linked to specific clinical features.
- Early diagnosis and intervention are crucial for managing Gaucher's disease.
Observation:
- A 4-year-old patient, homozygous for the D409H mutation, was diagnosed with Gaucher's disease neonatally.
- The patient presented with symptoms consistent with the D409H phenotype.
- Enzyme replacement therapy (ERT) commenced at two months of age.
Findings:
- The study details the clinical course of a pediatric Gaucher's disease patient over four years of ERT.
- Monitoring the long-term effects of ERT on the D409H mutation's specific phenotype is key.
- The patient's response to ERT provides insights into managing this specific Gaucher's disease genotype.
Implications:
- This case contributes to understanding the D409H Gaucher's disease phenotype and ERT efficacy.
- Findings may inform treatment strategies for pediatric patients with this specific mutation.
- Further research can elucidate genotype-specific responses to enzyme replacement therapy.
More Related Videos
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...